Flexion Therapeutics

Loading quotes...

Forecast

Buy	15
Hold	3
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Flexion Therapeutics has already paid €0.13 in dividends. The last payout was in August 2025.

Financials

In the last year, Flexion Therapeutics had revenue of €70.25m and net profit of -€93.36m

(EUR)	2020	YoY
Revenue	70.25m	8.03%
Gross profit	54.44m	3.04%
Net profit	-93.36m	30.06%
EBITDA	-73.77m	36.48%

Fundamentals

Metric	Value
Market capitalization	€422.4k
Number of shares	19.81k
52-week high/low	€23.28 - €21.27
Dividends	No
Beta	0.08
P/E ratio	-8.98
PEG ratio	1.80
P/B ratio	-61.37
P/S ratio	0.01

Company profile

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.